SRC and neoplasm: SH2D2A, also known as T cell-specific adaptor (TSAd), was required for vascular endothelial growth factor recepter 2 (VEGFR2)/c-Rous sarcoma (c-Src) interaction and c-Src activation, and promoted vascular permeability in tumor vessels 36, 37.